| __timestamp | Corcept Therapeutics Incorporated | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 79529000 |
| Thursday, January 1, 2015 | 36949000 | 91224000 |
| Friday, January 1, 2016 | 45240000 | 102413000 |
| Sunday, January 1, 2017 | 62416000 | 146987000 |
| Monday, January 1, 2018 | 81289000 | 213695000 |
| Tuesday, January 1, 2019 | 100359000 | 342000000 |
| Wednesday, January 1, 2020 | 105326000 | 661000000 |
| Friday, January 1, 2021 | 122356000 | 1283000000 |
| Saturday, January 1, 2022 | 152848000 | 2676000000 |
| Sunday, January 1, 2023 | 184259000 | 3297000000 |
| Monday, January 1, 2024 | 3790000000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Genmab A/S and Corcept Therapeutics Incorporated have demonstrated contrasting approaches to SG&A expenditures. From 2014 to 2023, Genmab A/S has seen a staggering increase of over 4,000% in SG&A expenses, peaking at approximately $3.3 billion in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Corcept Therapeutics has adopted a more conservative approach, with a 428% increase over the same period, reaching around $184 million in 2023. This divergence highlights differing strategic priorities: Genmab's focus on scaling operations versus Corcept's emphasis on controlled growth. As these companies continue to evolve, their SG&A strategies will likely play a pivotal role in shaping their future trajectories.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Revenue Showdown: Genmab A/S vs Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights